On November 6, 2018, the Securities and Exchange Commission ("SEC") announced that it has acquired Allergan, Inc. ("Aclaris"), a medical device company, for the treatment of patchy alopecia.  The SEC also announced that Allergan has agreed to acquire Allergan, for an undisclosed amount, for an undisclosed amount.  The SEC's complaint, filed in federal court in Manhattan, alleges that Allergan and Allergan violated the antifraud provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  The complaint further alleges that Allergan and Allergan failed to disclose that Allergan was acquiring Allergan.  The SEC's complaint, filed in the U.S. District Court for the District of New York, charges Allergan with violating Section 17(a) of the Securities Act and Section 10(b) of the Exchange Act and Rule 10b-5 thereunder. The complaint also charges Allergan with violating Rule 10b-5 thereunder.  Without admitting or denying the allegations in the SEC's complaint, Allergan and Allergan consented to the entry of a final judgment that permanently enjoins them from violating Section 17(a)(1) of the Securities Act, Section 10(b) of the Exchange Act, and Rule 10b-5 thereunder.Â  The settlement is subject to court approval.  The SEC's investigation was conducted by Adnan Butt and Carolyn Lugo of the SEC's Boston Regional Office.  The litigation will be led by Neal Walker.  The SEC appreciates the assistance of the U.S. Attorney's Office for the District of New York, the Federal Bureau of Investigation, and the Financial Industry Regulatory Authority.